Sign In
Buy CRMD
$8.23
+0.0600 (+0.734%)
At Close: Jun 03, 2026
CorMedix Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - CRMD
09:15pm, Thursday, 27'th Mar 2025
NEW YORK, NY / ACCESS Newswire / March 27, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of CorMedix Inc. ("CorMedix Inc.") (NASDAQ:CRMD) concerning possible violat
NEW YORK, March 27, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against CorMedix Inc. (“CorMedix” o
Lost Money on CorMedix Inc.(CRMD)? Contact Levi & Korsinsky Regarding an Ongoing Investigation
07:15pm, Wednesday, 26'th Mar 2025
NEW YORK, NY / ACCESS Newswire / March 26, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of CorMedix Inc. ("CorMedix Inc.") (NASDAQ:CRMD) concerning possible violat
CorMedix Inc. (CRMD) Shareholders May Have Been Affected by Fraud- Levi & Korsinsky Investigates
02:45pm, Wednesday, 26'th Mar 2025
NEW YORK, NY / ACCESS Newswire / March 26, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of CorMedix Inc. ("CorMedix Inc.") (NASDAQ:CRMD) concerning possible violat
INVESTOR ALERT: Investigation of CorMedix Inc. (CRMD) Announced by Holzer & Holzer, LLC
05:06pm, Tuesday, 25'th Mar 2025
ATLANTA, March 25, 2025 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether CorMedix Inc. (“CorMedix” or the “Company”) (NASDAQ: CRMD) complied with federal securities laws. On
CorMedix Inc. (CRMD) Q4 2024 Earnings Call Transcript
10:51am, Tuesday, 25'th Mar 2025
CorMedix Inc. (NASDAQ:CRMD ) Q4 2024 Earnings Conference Call March 25, 2025 8:30 AM ET Company Participants Dan Ferry - Managing Director, LifeSci Advisors Joe Todisco - Chief Executive Officer Matt
CorMedix (CRMD) Q4 Earnings and Revenues Beat Estimates
09:40am, Tuesday, 25'th Mar 2025
CorMedix (CRMD) came out with quarterly earnings of $0.22 per share, beating the Zacks Consensus Estimate of $0.17 per share. This compares to loss of $0.26 per share a year ago.
CorMedix Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
07:30am, Tuesday, 25'th Mar 2025
‒ Q4 2024 Net Revenue of $31.2mm; 2024 Net Revenue of $43.5mm ‒ ‒ Q4 Net Income of $13.5mm and Adjusted EBITDA of $15.3mm ‒ ‒ Conference Call Scheduled for Today at 8:30 a.m. Eastern Time �
CorMedix Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
09:21am, Monday, 24'th Mar 2025
CorMedix Inc. CRMD will release its fourth-quarter financial results, before the opening bell, on Tuesday, March 25.
CorMedix Inc. to Report Fourth Quarter and Full Year 2024 Financial Results and Provide a Corporate Update on March 25, 2025
08:30am, Tuesday, 18'th Mar 2025
BERKELEY HEIGHTS, N.J., March 18, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening
CorMedix Stock Rises on Q4 Preliminary Sales Beating Estimates
02:42pm, Wednesday, 08'th Jan 2025
CRMD reports $31 million in preliminary sales from its sole marketed product in Q4, surpassing its previous guidance of breaking even by 2024.
CorMedix Inc. Announces Preliminary Fourth Quarter 2024 Results and Provides Business Update
07:30am, Tuesday, 07'th Jan 2025
‒ Q4 2024 Unaudited Net Revenue of Approximately $31mm ‒ ‒ FY 2024 Unaudited Net Revenue of Approximately $43mm ‒ ‒ Expects Q4 Adjusted EBITDA to Exceed $12mm ‒ BERKELEY HEIGHTS, N.J., Jan
Is CorMedix (CRMD) Stock Outpacing Its Medical Peers This Year?
10:41am, Friday, 27'th Dec 2024
Here is how CorMedix (CRMD) and ResMed (RMD) have performed compared to their sector so far this year.
CorMedix Inc. Added to Nasdaq Biotechnology Index
08:30am, Thursday, 19'th Dec 2024
BERKELEY HEIGHTS, N.J., Dec. 19, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening
CorMedix Inc. Supports CMS Policy Updates Regarding Access to Innovative Drug Products
08:30am, Tuesday, 26'th Nov 2024
BERKELEY HEIGHTS, N.J., Nov. 26, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening
